Author: BusinessWire

 Recognized for comprehensive strengths in the design, deployment of decentralized solutions
WILMINGTON, N.C.–(BUSINESS WIRE)–PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, has been recognized for industry leadership in di…

ISG Provider Lens™ report finds biotech and pharmaceutical companies looking to innovate through digital transformation
STAMFORD, Conn.–(BUSINESS WIRE)–$III #ClinicalTrials–The life sciences industry is under considerable pressure to embrace digita…

Company expects to complete merger with Longevity Acquisition Corporation and its American Depositary Shares to be admitted to trading on NASDAQ on 22 March 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULAT…

Company expects to complete merger with Longevity Acquisition Corporation and its American Depositary Shares to be admitted to trading on NASDAQ on 22 March 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULAT…

Tildacerfont Led to Significant Reductions in Disease Biomarkers Over 12 Weeks

Tildacerfont is First CRF1 Antagonist Studied Beyond Two Weeks in CAH

CAHmelia Program Underway and Enrolling Patients in U.S. and Europe
SAN FRANCISCO–(BUSINESS WIRE)–…

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amathus Therapeutics announced today a strategic collaboration with Merck, known as MSD outside the United States and Canada, to develop novel small molecule therapeutic candidates for neurodegenerative diseases.

Edw…

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #DryAMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley,…

First IND application cleared by FDA for AXA1665

Initiation of AXA1665 Phase 2 clinical trial in OHE expected in Q2 2021

Initiation of AXA1125 Phase 2b clinical trial in NASH expected in Q2 2021

Company to host conference call at 8:30 a.m. ET t…

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has completed its 20th pre-clinical study and is progressing its …

Phase 2B clinical trial in patients with relapsed /refractory DLBCL expected to be initiated in Q2 2021 following guidance received from the FDA

Maveropepimut-S (DPX-Survivac) in combination with Merck’s Keytruda® (pembrolizumab) and low dose cycloph…